Beyond primary weight-loss efficacy, companies are increasingly using cardiometabolic risk-factor readouts and broader endpoint coverage to support obesity drug value propositions. Coverage of Lilly’s retatrutide program emphasized improvements in cardiovascular risk factors alongside weight loss, with the trial results framed as potentially setting a new benchmark for future obesity candidates. The same Phase 3 reporting also tied tolerability findings to dosing decisions, highlighting a balance between magnitude of loss and gastrointestinal adverse events. In a related clinical-evidence direction, another report centered on oral semaglutide’s cardiometabolic effects in obesity and overweight populations, reflecting how oral and non-injectable formulations are competing on improvements to metabolic risk profiles. For industry decision-makers, the message is that regulators and payers are looking for more than scale outcomes—cardiometabolic benefit signals are becoming central to differentiation and labeling strategy.